Toripalimab
- Generic Name
- Toripalimab
- Brand Names
- Loqtorzi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1924598-82-2
- Unique Ingredient Identifier
- 8JXN261VVA
- Background
Toripalimab is under investigation in clinical trial NCT03919383 (Phase II of Lenvatinib Plus Toripalimab for Advanced HCC).
- Indication
⑴用于治疗既往标准治疗失败后的局部进展或转移性黑色素瘤。⑵用于治疗既往接受过二线及以上系统治疗失败的复发/转移性鼻咽癌（NPC）。⑶用于治疗既往接受过治疗的局部进展或转移性尿路上皮癌（UC）。⑷用于食管鳞癌一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Hubei Cancer Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05021328
- Locations
- 🇨🇳
Hubei Cancer Hospital, Wuhan, Hubei, China
Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial
- Conditions
- Interventions
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2021-08-20
- Lead Sponsor
- Cancer Hospital of Guangxi Medical University
- Target Recruit Count
- 40
- Registration Number
- NCT04992988
- Locations
- 🇨🇳
Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China
Toripalimab Plus Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Advanced MSI-H or dMMR Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2021-08-03
- Lead Sponsor
- Peking University
- Target Recruit Count
- 44
- Registration Number
- NCT04988191
- Locations
- 🇨🇳
Peking University Cancer Hospital and Institute, Beijing, Beijing, China
Toripalimab Combined With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2021-07-22
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT04973904
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular Carcinoma
- First Posted Date
- 2021-06-15
- Last Posted Date
- 2021-06-15
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT04926532
- Locations
- 🇨🇳
Zhongshan Hospital, Shanghai, China
A Study of GFH018 in Combination with Toripalimab in Patients with Advanced Solid Tumors
- First Posted Date
- 2021-06-04
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
- Target Recruit Count
- 148
- Registration Number
- NCT04914286
- Locations
- 🇨🇳
Sun Yat-sen university cancer center, Guangzhou, Guangdong, China
🇨🇳Shang hai east hospital, Shanghai, Shanghai, China
🇦🇺Linear Clinical Research Ltd, Perth, Western Australia, Australia
A Study of Toripalimab or Combining With Temozolomide（iv） in the Treatment of Advanced/Metastatic Malignant Melanoma
- Conditions
- Interventions
- First Posted Date
- 2021-05-13
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 90
- Registration Number
- NCT04884997
- Locations
- 🇨🇳
Department of Medical Onocology, First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China
Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2021-07-13
- Lead Sponsor
- Peking University
- Target Recruit Count
- 43
- Registration Number
- NCT04880811
- Locations
- 🇨🇳
Peking University Cancer Hospital and Institute, Beijing, Beijing, China
Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
- First Posted Date
- 2021-04-14
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 124
- Registration Number
- NCT04844385
- Locations
- 🇨🇳
Sun yat-sen University Cancer Center, Guangzhou, Guangdong, China
Study of the Safety and Effectiveness of HIFU Combined With REGOTORI for Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-03-29
- Last Posted Date
- 2021-03-29
- Target Recruit Count
- 10
- Registration Number
- NCT04819516
- Locations
- 🇨🇳
the Second Affiliated Hospital of Medical College of Zhejiang University, Hangzhou, Zhejiang, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.